European Patent Office

R 0008/13 du 20.03.2015

Identifiant européen de la jurisprudence
ECLI:EP:BA:2015:R000813.20150320
Date de la décision
20 mars 2015
Numéro de l'affaire
R 0008/13
Requête en révision de
T 1676/08 2012-03-09
Numéro de la demande
96102992.3
Langue de la procédure
Anglais
Distribution
Distribuées aux présidents et aux membres des chambres de recours (B)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
R 0008/13 2015-09-15
Résumés pour cette décision
-
Titre de la demande
Controlled release oxycodone compositions
Nom du demandeur
The Purdue Pharma Company
Mundipharma GmbH
Napp Pharmaceutical Holdings Limited
Norpharma A/S
Mundipharma Pharmaceuticals S.R.L.
Mundipharma Laboratories GmbH
Mundipharma Pharmaceuticals BV
Mundipharma AB
Mundipharma AG
Mundipharma Farmaceutica LDA
Mundipharma Pharmaceuticals SL
Mundipharma GesmbH
Mundipharma CVA
Nom de l'opposant
Lannacher Heilmittel Ges.m.b.H.
Chambre
-
Sommaire
-
Dispositions juridiques pertinentes
Convention for the Protection of Human Rights and Fundamental Freedoms Art 6(1)European Patent Convention Art 10European Patent Convention Art 11European Patent Convention Art 23European Patent Convention Art 24Rules of procedure of the Enlarged Board of Appeal Art 4
Mots-clés
Lack of impartiality based on objective suspicion under Article 24(3) and 6 ECHR ascertained facts [no] Existing safeguard Article 23 EPC [yes]
Exclusion of the chairman objected [no]
ECHR: Campbell and Fell v.the United Kingdom (No 7819/77, 7878/77); Cooper v. The United Kingdom (No 48843/99); Micallef v. Malta (No 17056/06); de Cubber v. Belgium (No 9186/80); Wettstein v. Switzerland (No 33958); Kleyn and others v. the Netherlands (No 39343/98, 39651/98, 43147/98, 46664/99; Pabla Ky v. Finland (No 47221/99); Levages Prestations Services v. France (No 21920/93); Steck-Risch and others v. Liechtenstein (63151/00); Savino and others v. Italie (No 17214/05, 20329/05, 42113/04); Kyprianou v. Cyprus (No 73757/01); Beaumartin v. France (No 15287/89) ; Sramek v. Austria (No 8790/79); Procola v. Luxembourg (No 14570/89); Rolf Gustafson v. Sweden (No 23196/94)
G 0003/08 of 16 October 2009 and G 0003/08 of 12 May 2010
Exergue
The potential conflicts intrinsic to the dual function of vice-president of the EPO Directorate-General 3 (VP3) and chairman of the Enlarged Board were perceived even prior to R 19/12 as is shown by the EPC's legislative history. They have been circumvented merely by means of specific organisational measures (points 6.2 and 6.3).
If a single individual in the form of VP3 has the dual role of safeguarding judicial independence and at the same time of exercising management authority, this can only be interpreted to mean - as shown by the EPC's legislative history and the application of the relevant provisions - that the requirement to safeguard independence must be taken into account when exercising such management authority. In other words, Article 23 EPC limits the President's power to give instructions under Article 10(2)(f) EPC to the Enlarged Board's chairman in his capacity of VP3.
Article 23 EPC can only be seen as the means to counter any influence the EPO executive might seek to exert on VP3 under Article 10(2)(f) and (3) EPC (point 6.5)
In the circumstances of the present case and in view of VP3's restricted duties, there are no ascertainable facts giving objective cause to believe that Article 23 EPC can no longer fulfil its safeguard role vis-à-vis Article 10(2)(f) and (3) EPC when acting in his judicial function (point 7.2).
Whether the current organisational structure remains the most appropriate one is for EPO legislator to decide (points 3.5 and 7.3).

Order

For these reasons it is decided that:

For these reasons it is decided that the request of the petitioners that Mr. X be replaced as chairman of the Enlarged Board in its composition pursuant to Rule 109(2)(b) EPC is rejected.